comprehensive -WSS

comprehensive

author：hotspot 2025-09-03 09:34:58 - browse：726

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Listen: A conversation with researcher Kevin Esvelt on biosecurity

focus

WSS

It costs an awful lot of money to give away a kidney

ASCO eve: Let’s set the table for this year's meeting

Questions and answers about ramping up H5N1 bird flu vaccine

FAA sets up new process for Hawaii air tour operators to fly at lower altitudes after fatal crashes

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Scrutiny of post

knowledge

comprehensive

explore

At least 13 dead in Texas as scorching temps continue

Heart disease in astronauts blamed on cosmic radiation

Cancer drug shortages should be causing more outrage

Physicians aren't 'burning out.' They're suffering from moral injury

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Group behind ProMed defends move to subscription

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC recommends RSV monoclonal antibody for infants

At least 13 dead in Texas as scorching temps continue

H.R. 3 is the wrong path to lower drug costs

entertainment

Biogen joins immunology wave with $1.15 billion acquisition of HI

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Fentanyl is making it harder to start addiction treatment

Physicians aren't 'burning out.' They're suffering from moral injury

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

focus

Wikipedia

focus

focus